Cited by 344Virus-based gene therapy researchRNA Interference and Gene DeliveryViral Infectious Diseases and Gene Expression in Insects

Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6

Open access
Grimm, Dirk, Kay, Mark A, Kleinschmidt, Juergen A·2003·Molecular Therapy

Abstract

We present a simple and safe strategy for producing high-titer adeno-associated virus (AAV) vectors derived from six different AAV serotypes (AAV-1 to AAV-6). The method, referred to as "HOT," is helper virus free, optically controllable, and based on transfection of only two plasmids, i.e., an AAV vector construct and one of six novel AAV helper plasmids. The latter were engineered to carry AAV serotype rep and cap genes together with adenoviral helper functions, as well as unique fluorescent protein expression cassettes, allowing confirmation of successful transfection and identification of the transfected plasmid. Cross-packaging of vector DNA derived from AAV-2, -3, or -6 was up to 10-fold more efficient using our novel plasmids, compared to a conservative adenovirus-dependent method. We also identified a variety of useful antibodies, allowing detection of Rep or VP proteins, or assembled capsids, of all six AAV serotypes. Finally, we describe unique cell tropisms and kinetics of transgene expression for AAV serotype vectors in primary or transformed cells from four different species. In sum, the HOT strategy and the antibodies presented here, together with the reported findings, should facilitate and support the further development of AAV serotype vectors as powerful new tools for human gene therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1525-0016(03)00095-9

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For the majority of rAAV vectors, the ITRs and rep gene of AAV2 are utilized, resulting in pseudotyped rAAVs.

    “For the majority of rAAV vectors, the ITRs and rep gene of serotype 2 (AAV2) are utilized resulting in pseudo-typed rAAVs [11].”

    From Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses (2017) · cites this paper as [11]

    The Results describe pseudotyped particles containing AAV-2 vector DNA made with a helper that retains AAV-2 rep while substituting capsid genes from other serotypes. The Discussion says pseudotyping of non-type-2 vectors had been described only once, supporting the prominence of AAV-2-based pseudotyping. Neither passage establishes that the majority of all rAAV vectors use AAV-2 ITRs and rep or that most rAAV vectors are pseudotyped. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [4]4. Erles, K. ∙ Sebokova, P. ∙ Schlehofer, J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV) J. Med. Virol. 1999; 59:406-411 Crossref Scopus (305) PubMed Google Scholar

Cited by

Sorted by citations

Authors
Grimm, D., Kay, M. A., & Kleinschmidt, J. A.
Affiliations
  • Stanford Medicine (US)
  • German Cancer Research Center (DE)
Corresponding author
Kay, Mark A
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2003-06
Volume
7
Issue
6
Pages
839-850
ISSN
1525-0016 (ISSN-L)
OpenAlex
W1977797303
Cited by
344
References
36
Citations by year
2026: 4 · 2025: 9 · 2024: 12 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 12 · 2019: 18 · 2018: 5 · 2017: 17 · 2016: 7 · 2015: 21 · 2014: 12 · 2013: 20 · 2012: 19
FWCI
7.96
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (HL66948, U01HL066948)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
Keywords
adeno-associated virus vectors, fluorescent protein markers, cell tropism, transgene expression kinetics, gene therapy vectors
MeSH terms
Dependovirus, Cell Line, DNA Replication, DNA-Binding Proteins, Genetic Vectors, Helper Viruses, Humans, Plasmids, Serotyping, Viral Proteins, Virus Replication, Virus Assembly

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review